Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31390611 | 0.84 | ACHE (0.72) | ACHEALDH1A1LMNAPOLBKMT2A | |
| SCHEMBL3311099 | 0.80 | ACHE (0.72) | ACHEALDH1A1LMNAPOLBKMT2A | |
| SCHEMBL3310179 | 0.80 | ACHE (0.76) | ACHEALDH1A1LMNAPOLBKMT2A | |
| SCHEMBL31390608 | 0.79 | ALDH1A1 (0.52) | ACHEALDH1A1LMNAPOLBKMT2A | |
| SCHEMBL31390603 | 0.78 | ALDH1A1 (0.51) | ACHEALDH1A1LMNAPOLBKMT2A | |
| SCHEMBL16237179 | 0.76 | ACHE (0.55) | ACHEALDH1A1LMNAPOLBKMT2A | |
| SCHEMBL2360974 | 0.76 | ALDH1A1 (0.84) | ALDH1A1LMNAPOLBKMT2AMEN1 | |
| SCHEMBL18794812 | 0.75 | ALDH1A1 (0.69) | ACHEALDH1A1LMNAPOLBKMT2A | |
| SCHEMBL4070583 | 0.73 | ALDH1A1 (0.69) | ACHEALDH1A1LMNAPOLBKMT2A | |
| SCHEMBL5347059 | 0.73 | ALDH1A1 (0.97) | ACHEALDH1A1LMNAPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2221306-B1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | NISSAN CHEMICAL IND LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-8669367-B2 | Method for producing 2-azaadamantane | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-03-11 | — | — | US | disclosed |
| US-20120310005-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | TOHOKU TECHNO ARCH CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| US-8273889-B2 | Method for producing 2-azaadamantane | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20100311977-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2221306-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | Nissan Chemical Industries, Ltd. (JP) | 2010-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311977-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | CYP21A2, CYP51A1, CYP19A1 | ACHE 2246/4885ALDH1A1 328/4885LMNA 3604/4885 |
| US-20120310005-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | CYP21A2, CYP51A1, CYP19A1 | ACHE 2246/4885ALDH1A1 328/4885LMNA 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.